SNYNasdaqPharmaceutical PreparationsFiscal year ends December 31Also trades as SNYNF

Sanofi

Financials through fiscal 2025, year ended Dec 31, 2025Last filing: 20-F on Feb 17, 2026

$39.57−1.04 (-2.56%)

Close on Oct 19, 2026

Sanofi income statement

AnnualQuarterlyTTM

EUR USD

Millions of EUR, except per-share data. Shares in millions.

Line item	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31	FY 2021 2021-12-31	FY 2020 2020-12-31	FY 2019 2019-12-31	FY 2018 2018-12-31	FY 2017 2017-12-31	FY 2016 2016-12-31	FY 2015 2015-12-31
Cost of Revenue	13,049	13,205	12,628	11,882	12,255	12,159	11,979	11,435	11,613	10,701	10,919
Gross Profit	33,667	31,081	28,990	28,679	26,920	25,210	25,652	24,242	24,608	23,995	23,942
Research & Development	7,842	7,394	6,507	6,501	5,692	5,530	6,020	5,894	5,472	5,172	5,082
Selling, General & Admin	9,543	9,183	8,933	8,739	9,555	9,391	9,884	9,859	10,072	9,478	9,382
Operating Income	6,344	7,252	6,960	10,162	8,126	14,113	3,051	4,676	5,804	6,531	5,624
Interest Expense	563	1,073	1,293	430	368	388	440	435	420	924	559
Interest & Investment Income	394	519	584	205	40	53	141	164	147	68	178
Income from Equity Investments	–	–	-115	68	39	359	255	499	85	136	–
Income Tax Expense	1,043	1,204	1,017	1,909	1,558	1,807	121	481	1,722	1,325	709
Income from Continuing Operations	4,977	5,554	5,098	8,083	6,279	12,330	2,886	4,423	3,894	4,486	4,512
Income from Discontinued Operations	2,874	64	338	401	0	0	-101	-13	4,643	314	-124
Net Income incl. Noncontrolling Interests	7,851	5,618	5,436	8,484	6,279	12,330	2,785	4,410	8,537	4,800	4,388
Minority Interest in Earnings	38	58	36	113	56	36	31	104	121	91	101
Net Income	7,813	5,560	5,400	8,371	6,223	12,294	2,754	4,306	8,416	4,709	4,287
Net Income to Common	7,813	5,560	5,400	8,371	6,223	12,294	2,754	4,306	-8,416	-4,709	-4,287
EPS (Basic)(per share)	6.40	4.44	4.31	6.69	4.97	9.82	2.24	3.45	6.70	3.66	3.28
EPS (Diluted)(per share)	6.37	4.43	4.30	6.66	4.95	9.77	2.23	3.43	6.64	3.63	3.25
Shares Outstanding (Basic, Weighted)(shares)	1,220	1,251	1,252	1,252	1,253	1,254	1,250	1,247	1,257	1,287	1,306
Shares Outstanding (Diluted, Weighted)(shares)	1,226	1,256	1,256	1,257	1,257	1,260	1,257	1,255	1,267	1,296	1,321

Italic numbers are calculated by StockData (for example Q4 = full year − nine months). Per-share data and share counts are adjusted for stock splits. Hover a number for its source; click it to open the filing on SEC.gov. Click a row to chart it.

Ratios

Latest available, balances at Jun 30, 2026

Profitability, FY

Gross margin: –
Operating margin: –
Net margin: –
Return on equity, FY2025: 10.5%

Financial strength

Current ratio: 0.99
Debt to equity: 0.31
Debt to assets: 16.8%
Cash to current liabilities: 19.9%

Valuation

P/E ratio: –
Price to sales: –
Price to book: –
Dividend yield: –

Valuation ratios need the share price and fill in once daily prices are connected.